About Head and Neck Cancers

The Head and Neck Institute at the Mount Sinai Health System offers unparalleled expertise in the diagnosis and treatment of all diseases and tumors related to the head and neck. It is globally recognized for its minimally invasive treatments and renowned head and neck specialists. Our multidisciplinary team offers robotic and minimally invasive treatments, as well as the latest immunotherapy options and clinical trials.

Dr. Eric Genden, Chair of the Department of Otolaryngology-Head and Neck Surgery was the first in New York to treat oral and throat cancers with transoral robotic surgery (TORS) and has since become one of the most experienced TORS surgeons worldwide. Today, the Head and Neck Institute houses the largest Robotic Surgery Program for Head and Neck Cancers in the country and treats more head and neck oncology patients than any other hospital or hospital system in New York 

Multidisciplinary Approach to Treating Head and Neck Cancers

Head and neck cancers are complex disease processes, which affect various structures of the mouth, jaw and throat. The delicate nature of these systems and goal of preservation of each is why you or your loved one will need a team of specialists. Our care philosophy incorporates this team effort at each phase of your care.

Patients are entered into our Patient First Program, which is a personalized team dedicated to coordinating the care of our patients. This multidisciplinary team collaborates with you and your referring physician to identify the best approach to care. Specialists include head and neck surgeons, microvascular and reconstructive surgeons, oral and maxillofacial surgeons, medical and radiation oncologists, oncology nurse practitioners and nurses, speech and hearing therapists, social workers and nutritionists. 

Innovative Head and Neck Cancer Research

Mount Sinai offer you and your loved one access to institutional and multi-institutional clinical trials. At the Head and Neck Cancer Research Program, our physicians and researchers are studying immunotherapies, the reduction of medical oncology after TORS, the transmission of HPV (human papilloma virus) and its effect on oropharyngeal cancers, the reduction in side effects, the quality of life with TORS versus open surgery and the correlation of environmental toxins and thyroid cancer. This distinguished Research Program is also internationally recognized as a leading resource for tumor cell dormancy research.  

Why Choose Mount Sinai for Head and Neck Oncology Care

At the Head and Neck Institute, our patients have the following distinct care advantages:

  • Foremost minimally invasive head and neck surgeons
  • State-of-the-art technology, including TORS and sialendoscopy 
  • Microvascular, reconstructive and oral and maxillofacial surgeons
  • Unmatched experience with HPV-related oropharyngeal cancers
  • Multidisciplinary (team) approach 
  • Medical and Radiation Oncology Surveillance Program during and post-treatment
  • Participation in clinical trials (optional and pending candidacy)
  • Easy access to care, including telemedicine and participation in most insurances

To make an appointment: